Skip to main content
SMO ClinPlus CO., LTD. logo

SMO ClinPlus CO., LTD. — Investor Relations & Filings

Ticker · 301257 ISIN · CNE100005CP8 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-04-28 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 301257

About SMO ClinPlus CO., LTD.

https://www.smo-clinplus.com

SMO ClinPlus CO., LTD. is a professional Site Management Organization (SMO) providing comprehensive clinical trial site management services. The company specializes in supporting pharmaceutical, biotechnology, and medical device developers throughout the clinical development lifecycle. Core services include the provision of Clinical Research Coordinators (CRCs), site feasibility assessments, patient recruitment and retention strategies, and clinical trial data management. ClinPlus facilitates the execution of clinical trials by managing administrative and operational tasks at research sites, ensuring compliance with Good Clinical Practice (GCP) and regulatory requirements. With an extensive network of partner hospitals and research institutions, the company streamlines the clinical research process, enhances data quality, and accelerates project timelines for domestic and international sponsors.

Recent filings

Filing Released Lang Actions
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including revenue, net profit, assets, and shareholder information. It also includes management discussion on business operations, industry environment, and company strategy. The document references the full annual report and audit opinion by an accounting firm, indicating it is a summary of the full annual report. The length of the document (7249 characters) and the detailed financial and operational data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K).
2025-04-28 Chinese
董事会对独董独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the company's board regarding the independence of its independent directors, referencing regulatory guidelines and confirming compliance with independence requirements. It does not contain financial data, audit results, or detailed governance structures but focuses on the status and qualifications of board members. This fits the category of Board/Management Information (MANG), which includes announcements about board matters such as director independence.
2025-04-28 Chinese
2024年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与使用情况专项报告" which translates to a special report on the deposit and use of raised funds for the year 2024. It details the amount of funds raised through an IPO, the usage and balance of these funds, the management and storage of the funds, and compliance with regulatory requirements. It includes detailed tables on the use of funds, investment projects, and cash management activities related to the raised capital. The document references regulatory guidelines on the management and use of raised funds and includes a certification by the board of directors. This type of document is a specialized report focused on capital raised and its usage, which fits the category of Capital/Financing Update (CAP). It is not a general annual or interim report, nor an announcement of a report publication. The document length is sufficient and contains substantive financial and operational data related to capital usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-04-28 Chinese
华泰联合证券有限责任公司关于普蕊斯（上海）医药科技开发股份有限公司2024年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Huatai United Securities Co., Ltd. regarding the 2024 annual verification of the storage and use of funds raised by Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd. It includes specific financial figures about the amount raised, usage, balance, and management of the raised funds during the 2024 fiscal year. It also contains the auditor's verification opinion and the sponsor's main verification work and opinions. The document focuses exclusively on the management and use of fundraising proceeds, consistent with regulatory requirements for annual fundraising usage reports. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but contains substantive financial data and detailed analysis of fundraising usage. Therefore, the correct classification is CAP with high confidence.
2025-04-28 Chinese
2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and responsibilities related to internal control over financial reporting as of December 31, 2024. The document contains an auditor's opinion on the effectiveness of internal controls, signed by certified public accountants. It is a standalone audit report focused on internal control effectiveness, not a full annual report or other type of filing. The length is short (743 characters), but the content is substantive and includes an audit opinion, so it is not merely an announcement. Therefore, it fits the category of Audit Report / Information (AR).
2025-04-28 Chinese
2024年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a summary table of non-operating fund occupation and other related party fund transactions for the year 2024, including details of balances, amounts, and interest related to these transactions. It is approved by the board of directors and signed by the legal representative and accounting heads. The document is short (1092 characters) and contains specific financial data related to related party transactions but does not constitute a full annual or interim report. It is not an announcement or a certification but a detailed financial disclosure related to related party transactions. Such disclosures typically fall under Regulatory Filings (RNS) as they do not fit the definitions of Annual Report, Interim Report, or other specific categories like Audit Report or Earnings Release. Therefore, the best classification is Regulatory Filings (RNS).
2025-04-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.